市場調查報告書

全球非類鴉片物質止痛貼片市場:各貼片類型、通路、地區(2018年∼2023年)

Non-opioid Pain Patch Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 704955
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
Back to Top
全球非類鴉片物質止痛貼片市場:各貼片類型、通路、地區(2018年∼2023年) Non-opioid Pain Patch Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

全球非類鴉片物質止痛貼片市場,預計從2018年到2023年的整個預測期內以3.5%的年複合成長率發展。

本報告提供全球非類鴉片物質止痛貼片市場調查,市場概要,各貼片類型、通路、地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 成長要素
    • 疼痛相關疾病的疾病負擔的上升
    • 疼痛管理治療的研究開發的增加
    • 類鴉片物質藥的副作用的認識提高
  • 阻礙因素
    • 替代療法的存在
    • 貼片的黏合性的問題和認知度低
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 貼片各類型
    • 辣椒素貼片
    • 雙氯芬酸貼片
    • 酮洛芬貼片
    • 利多卡因貼片
    • 水楊酸甲基貼片
    • 其他
  • 各銷售管道
    • 醫院藥局
    • 零售藥局
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Acorda Therapeutics, Inc.
  • Allergan
  • Endo Pharmaceuticals PLC
  • GlaxoSmithKline PLC
  • 久光製藥
  • IBSA Institut Biochimque SA
  • Mylan NV
  • Pfizer, Inc
  • TEH SENG Pharmaceutical Mfg. Co., Ltd.
  • 帝國製藥

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 64062

Pain has a deeper impact on the socio-economic system than the combination of cardiovascular diseases, cancer, and diabetes together. The International Agency for Research on Cancer (IARC) predicts that, by 2030, the global burden is expected to increase to 21.7 million new cancer cases and 13 million cancer deaths. Similarly, cardiovascular disease (CVD) is one of the main causes of death among the adult population, globally. Chronic pain initiates in numerous ways, for instance, from trauma which could include an accident or back strain due to heavy lifting among other ways, an underlying disease like pancreatitis, spine disease, arthritis, and autoimmune diseases, or it can occur with fibromyalgia or persistent migraines. As per, CDC around 43% of the population suffer from pain on some days and around 20% of the population suffer from pain every day or on most days. There are numerous risk factors for chronic pain. Non-opioid patches are more preferable because it does not involve the risk of addiction as with opioid drug patches like fentanyl patches and also the drugs is released over a long period of time, therefore, helping in managing the pain for a longer duration and considered as a valuable driver for this market.

However, availability of alternative treatments and low adoption rate of non-opioid pain patch due to unawareness is expected to impede the growth of non-opioid pain patch market.

Key Market Trends

Lidocaine Patches Segment is Expected to Show Better Growth in the Forecast Years

Based on type, the market is segmented into lidocaine patches, diclofenac patches, capsaicin patches, ketoprofen patches, and others. Lidocaine patches are considered as the most commonly available patch for the treatment of chronic and acute pain. According to the American Academy of Pain Medicine (AAPM), chronic pain affects approximately 1.5 billion people worldwide with prevalence increasing with age. The proportion of the world's population over 60 years will nearly double from 12% to 22%, between 2015 and 2050, as per WHO estimates. Lidocaine patches are recommended as first-line therapy for the treatment of neuropathic pain in older patients, which is expected to boost the market growth. Furthermore, the increasing burden of diseases, along with safety profile and efficacy associated with lidocaine patches are expected to drive the market growth during the forecast period.

North America is Expected to Dominate the Non-opioid Pain Patch Market

North America is expected to retain its dominance in this market. chronic pain is one of the primary factors responsible for the growth of the market. According to the National Institute of Health (NIH), in 2016, around 20% of US adults were suffering from chronic pain and 8% had high impact, which at least limits one major life activity in the patient. In addition, the countries in North America are increasingly facing scrutiny on the opioid crises issue, from the government authorities, which in turn are expected to benefit the rise of non-opioid alternatives. Thus, rising disease burden is further pushing the need for effective and quick treatment options which is expected to propel the growth of the market, over the forecast period.

Competitive Landscape

The global players in the non-opioid pain patch market are - Clarion Brands Inc., Endo Pharmaceuticals, Hisamitsu Pharmaceutical, Sanofi, Sorrento Therapeutics (SCILEX Pharmaceuticals), TEH SENG Pharmaceutical, Teikoku Seiyaku, Teva Pharmaceuticals, and Veridian Healthcare.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Pain-Related Disorders
    • 4.2.2 Rising R&D in Pain Management Treatments
    • 4.2.3 Benefits Associated with Non-opioid Pain Patches over Conventional Medications
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatments
    • 4.3.2 Low Adoption Rate of Non-opioid Pain Patch due to Unawareness
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Patch Type
    • 5.1.1 Lidocaine Patches
    • 5.1.2 Diclofenac Patches
    • 5.1.3 Capsaicin Patches
    • 5.1.4 Ketoprofen Patches
    • 5.1.5 Others
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Clarion Brands Inc.
    • 6.1.2 Endo Pharmaceuticals Inc.
    • 6.1.3 Hisamitsu Pharmaceutical Co. Inc.
    • 6.1.4 Sanofi S.A.
    • 6.1.5 Sorrento Therapeutics (SCILEX Pharmaceuticals)
    • 6.1.6 TEH SENG Pharmaceutical Mfg Co
    • 6.1.7 Teikoku Seiyaku Co. Ltd.
    • 6.1.8 Teva Pharmaceuticals Industries Ltd.
    • 6.1.9 Veridian Healthcare

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top